Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.32 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | GABRP | O00591 | 1/20 | 0.31 |
| ▸ | GABRD | O14764 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1613612 | 1.00 | CYP2D6 (0.40) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL4071150 | 0.86 | CYP2D6 (0.37) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL19919497 | 0.74 | — | — | |
| SCHEMBL2028987 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2028983 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2031312 | 0.70 | HRH3 (0.32) | — | |
| SCHEMBL2702821 | 0.67 | — | — | |
| SCHEMBL23421119 | 0.62 | CYP2C19 (0.71) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL13973941 | 0.62 | CYP2C19 (0.71) | CYP2D6LMNABLMALOX15CYP1A2 | |
| SCHEMBL22362543 | 0.62 | ALOX15 (0.53) | CYP2D6LMNABLMALOX15CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118580235-A | Preparation method of lactam compound | 正大天晴药业集团股份有限公司 | 2024-09-03 | — | — | CN | claimed |
| CN-119255992-A | Heterocyclic derivatives, compositions and uses thereof | 北京丹擎医药科技有限公司 | 2025-01-03 | — | — | CN | disclosed |
| CN-118580235-A | Preparation method of lactam compound | 正大天晴药业集团股份有限公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2023226964-A1 | HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2023-11-30 | — | — | WO | disclosed |
| EP-3686191-B1 | CRYSTALLINE SULFAMIDE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2022-12-14 | — | — | EP | disclosed |
| US-11254665-B2 | Crystalline sulfamide compound | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-02-22 | — | — | US | disclosed |
| CN-113666922-A | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-11-19 | — | — | CN | disclosed |
| US-11111240-B2 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-09-07 | — | — | US | disclosed |
| US-11111240-B2 | Sultam compound and application method thereof | Chai Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-09-07 | — | — | US | disclosed |
| CN-109071471-B | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2021-02-18 | — | — | US | disclosed |
| EP-3434671-B1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-20200291012-A1 | CRYSTALLINE SULFAMIDE COMPOUND | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-17 | — | — | US | disclosed |
| EP-3686191-A1 | CRYSTALLINE SULFAMIDE COMPOUND | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| EP-3434671-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| EP-3434671-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2019-01-30 | — | — | EP | disclosed |
| CN-109071471-A | Internal sulfonamide compounds and methods of use thereof | 正大天晴药业集团股份有限公司 | 2018-12-21 | — | — | CN | disclosed |
| WO-2017162157-A1 | SULTAM COMPOUND AND APPLICATION METHOD THEREOF | 正大天晴药业集团股份有限公司 | 2017-09-28 | — | — | WO | disclosed |
| US-20100292224-A1 | ISOTHIAZOLIDINE 1,1-DIOXIDE AND TETRAHYDRO-2H-1,2-THIAZINE 1,1-DIOXIDE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11111240-B2 | Sultam compound and application method thereof | IDH1, IDH3A, IDH3B | CYP2D6 208/4885LMNA 4290/4885BLM 3048/4885 |
| US-20200291012-A1 | CRYSTALLINE SULFAMIDE COMPOUND | IDH1, IDH2, IDH3A | CYP2D6 1111/4885LMNA 4550/4885BLM 1551/4885 |
| US-20100292224-A1 | ISOTHIAZOLIDINE 1,1-DIOXIDE AND TETRAHYDRO-2H-1,2-THIAZINE 1,1-DIOXIDE DERIVATIVES AS P2X7 MODULATORS | P2RY10, P2RX1, P2RX3 | CYP2D6 1897/4885LMNA 4845/4885BLM 4199/4885 |
| US-20210047314-A1 | Sultam Compound And Application Method Thereof | IDH1, IDH3A, IDH3B | CYP2D6 208/4885LMNA 4290/4885BLM 3048/4885 |
| US-11254665-B2 | Crystalline sulfamide compound | IDH1, IDH2, IDH3A | CYP2D6 1122/4885LMNA 4557/4885BLM 1577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.